58. Hallucinations and CNS Side Effects with Voriconazole: A Real World Description
Session: Posters in the Park: Posters in the Park
Wednesday, October 3, 2018: 5:30 PM
Room: N Hall D Opening Reception and Posters in the Park Area
Background: Voriconazole is used for the treatment and prevention of invasive fungal infections, particularly in immunocompriomised patients. Among the various side effects of voriconazole, central nervous system (CNS) symptoms including hallucinations and visual disturbances have been reported with its use. We sought to evaluate the characteristics of patients experiencing these side effects.

Methods: We conducted a retrospective chart review to select adult patients who had received at least one dose of voriconazole and had at least one voriconazole serum concentration measurement during admission at Duke University Hospital between 01/01/2005 – 12/31/2015. The records were then screened to determine if patients experienced CNS side effects while on voriconazole and determined whether these effects were drug related.

Results: Of the 341 patients screened, 20 had documented CNS symptoms that were associated with the start of voriconazole therapy. 65% were male, 80% were Caucasian and mean age was 55.8 ± 13.3 years. Mean voriconazole dose was 569.0 ± 253.5 mg/day, 6.8 ± 2.8 mg/kg/day. The incidences of CNS symptoms were: 10 visual hallucinations, 9 visual changes, 2 auditory hallucinations, 2 confusions and 3 vivid dreams. Median time from first dose to first documented symptoms was 2 days (IQR 0-9), and median duration of symptoms was 2 days (IQR 1-6). Mean voriconazole serum concentration closest to when the first symptoms were documented was 3.1 ± 2.4 mcg/ml. Symptoms resolved after decreasing dose or discontinuing voriconazole in 4 and 6 patients, respectively. Symptoms did not resolve in 10 (50%) patients during admission. There was no difference in mean voriconazole concentration or total daily dose between patients whose symptoms did or did not resolve. 11 (55%) patients were receiving concomitant opioids when they experienced their symptoms.

Conclusion: CNS side effects of voriconazole are not rare but a large number of patients will have resolution of these symptoms after decreasing or discontinuing voriconazole. Concomitant opioids may be contributing to the incidence of these side effects since they can be associated with similar symptoms. It is important to consider all potential causes of CNS symptoms before making unnecessary voriconazole dose adjustments in critically ill patients.

Ahmad Mourad, MD, Medicine, Duke University School of Medicine, Durham, NC, Melissa Johnson, PharmD, MHS, Duke University, Durham, NC and John R Perfect, M.D., FIDSA, Infectious Diseases, Duke University Medical Center, Durham, NC

Disclosures:

A. Mourad, None

M. Johnson, None

J. R. Perfect, Pfizer: Consultant and Scientific Advisor , Research grant .

See more of: Posters in the Park
See more of: Posters in the Park

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.